Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3039478 and dexamethasone in T-ALL/T-LBL
NCT02518113Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of crenigacestat in t-cell acute lymphoblastic leukemia (T-ALL), T cell lymphoblastic lymphoma (T-LBL), sponsored by Eli Lilly and Company. Started Oct 2015; status: completed.
02
Drugs
crenigacestat
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT02518113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02518113.